



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

SB-265610

Cat. No.:	HY-50688
CAS No.:	211096-49-0
Molecular Formula:	C ₁₄ H ₉ BrN ₃ O
Molecular Weight:	357.16
Target:	CXCR
Pathway:	GPCR/G Protein; Immunology/Inflammation
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 31.25 mg/mL (87.50 mM; ultrasonic and warming and heat to 60°C)					
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg
		1 mM		2.7999 mL	13.9993 mL	27.9987 mL
		5 mM		0.5600 mL	2.7999 mL	5.5997 mL
		10 mM		0.2800 mL	1.3999 mL	2.7999 mL
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (7.00 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (7.00 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	SB-265610 is a selective, competitive, nonpeptide and allosteric CXCR2 antagonist. SB-265610 blocks rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization and neutrophil chemotaxis with IC ₅₀ s of 3.7 nM and 70 nM, respectively ^{[1][2]} .
IC ₅₀ & Target	CXCR2
In Vitro	In vitro, SB-265610 antagonizes rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization, IC₅₀ of 3.7 nM, and rat neutrophil chemotaxis in a concentration-dependent manner, IC₅₀ of 70 nM. SB-265610 reduces the antiapoptotic effect of CINC-1 to the levels of those untreated with CINC-1^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SB-265610 (2 mg/kg/day; i.p.; daily; for two weeks) treatment significantly inhibits the recruitment of Gr-1+CD11b+ cells to the mammary adenocarcinoma with Tgfr2 deletion but not the control tumors^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MMTV-PyVmT/Tgfr2 ^{MGKO} and MMTV-PyVmT/Tgfr2 ^{flox/flox} tumors from donor mice ^[3]
Dosage:	2 mg/kg/day
Administration:	Intraperitoneal injection; daily; for two weeks
Result:	Significantly inhibited the recruitment of Gr-1+CD11b+ cells to the mammary adenocarcinoma.

CUSTOMER VALIDATION

- Oncogene. 2023 Aug 31.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Auten RL, et al. Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. J Pharmacol Exp Ther. 2001 Oct;299(1):90-5.
- [2]. Milatovic S, et al. Impaired healing of nitrogen mustard wounds in CXCR2 null mice. Wound Repair Regen. 2003 May-Jun;11(3):213-9.
- [3]. Li Yang, et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell. 2008 Jan;13(1):23-35.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA